V. Carter

First name

V.

Last name

Carter

Chen, S., Miravitlles, M., Rhee, C. K., Pavord, I. D., Jones, R., Carter, V., et al. (2022). Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy. Int J Chron Obstruct Pulmon Dis, 17, 2187-2200. http://doi.org/10.2147/copd.s378649

View

Heatley, H., Tran, T. N., Bourdin, A., Menzies-Gow, A., Jackson, D. J., Maslova, E., et al. (2022). Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. http://doi.org/10.1136/thorax-2022-219642

View

Tran, T. N., Kerkhof, M., Carter, V., & Price, D. B. (2021). Persistence of Eosinophilic Asthma Endotype and Clinical Outcomes: A Real-World Observational Study. J Asthma Allergy, 14, 727-742. http://doi.org/10.2147/jaa.s306416

View

Voorham, J., Roche, N., Benhaddi, H., van der Tol, M., Carter, V., van Boven, J. F. M., et al. (2018). Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. BMJ Open. http://doi.org/10.1136/bmjopen-2018-022051

View

Price, D. B., Carter, V., Martin, J., Gardener, E. A., Skinner, D., Yang, S., et al. (2019). Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting beta2-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary Care. Drugs. http://doi.org/10.1007/s40265-019-01224-8

View

Kerkhof, M., Voorham, J., Dorinsky, P., Cabrera, C., Darken, P., Kocks, J. W., et al. (2020). Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax. http://doi.org/10.1136/thoraxjnl-2019-214457

View